IGO (IPGDF) Receives a Sell from UBS
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Spry covers the Basic Materials sector, focusing on stocks such as Northern Star Resources Ltd, Evolution Mining , and Newmont Corporation CHESS. According to TipRanks, Spry has an average return of 12.0% and a 66.51% success rate on recommended stocks.
In addition to UBS, IGO also received a Sell from Morgan Stanley's Rahul Anand in a report issued on August 8. However, yesterday, Citi maintained a Hold rating on IGO (Other OTC: IPGDF).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Shift4 Gets Mixed Analyst Views as UBS Downgrades, Goldman Reinstates with Buy
Shift4 Payments Inc. (NYSE:FOUR) is one of the. On August 6, 2025, UBS lowered its rating on the stock from Outperform to Buy and cut the price target from $125 to $115. The firm cited a weaker-than-expected ramp in enterprise activity despite a healthy $35 billion backlog. End-to-end payment volume slightly missed expectations for the second quarter, and UBS flagged delayed implementations among larger clients. While the Global Blue acquisition is expected to contribute approximately $300 million in revenue and $125 million in EBITDA during the second half of the year, UBS noted that execution risk remains. On the same day, Goldman Sachs reinstated coverage of Shift4 with a Buy rating and issued a price target of $104. The firm described Shift4 as a compelling growth story, highlighting the company's acquisition-led strategy as a way to scale without incurring high customer acquisition costs. The Global Blue deal was emphasized as a key example of that approach, allowing the company to expand its footprint in high-end international markets while maintaining capital efficiency. Shift4 Payments Inc. (NYSE: FOUR) provides integrated payment processing and business solutions for merchants in hospitality, food and beverage, stadiums, casinos, e-commerce, and specialty retail. The company's ecosystem includes secure payment platforms, software integrations, and analytics tools that support over 200,000 businesses across the United States and abroad. While we acknowledge the potential of FOUR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
23 minutes ago
- Business Insider
SPY ETF News, 8/13/2025
How is SPY stock faring? The SPDR S&P 500 ETF Trust has risen 2.53% over the past five days and is up 9.15% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks' unique ETF analyst consensus, which is based on a weighted average of its holdings' analyst ratings, SPY is a Moderate Buy. The Street's average price target of $702.98 for the SPY ETF implies an upside potential of 9.38%. Currently, SPY's five holdings with the highest upside potential are Moderna (MRNA), Charter Communications (CHTR), Salesforce (CRM), Loews (L), and Eli Lilly (LLY). (PLTR), Garmin (GRMN), Tesla Motors (TSLA), Viatris (VTRS), and Altria (MO). Revealingly, SPY's ETF Smart Score is seven, implying that this ETF is likely to perform in line with the market. Power up your ETF investing with TipRanks. Discover the ETFs with High Upside Potential, carefully curated based on TipRanks' analysis.
Yahoo
an hour ago
- Yahoo
UBS Lowers PT on Enovis Corporation (ENOV) to $57 From $65, Keeps a Buy Rating
Enovis Corporation (NYSE:ENOV) is one of the . On August 8, UBS lowered the firm's price target on Enovis Corporation (NYSE:ENOV) to $57 from $65, keeping a Buy rating on the shares. A patient recieving cold therapy treatment using the company's products. The rating update came after Enovis Corporation (NYSE:ENOV) reported fiscal Q2 2025 earnings on August 7, with net sales for the quarter reaching $565 million, reflecting a 7% growth on a reported basis and 5% on an organic basis compared to the same quarter last year. Management reported that fiscal Q2 results reflect stable end markets, continued execution in P&R and Recon, and positive momentum in new product introductions. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
